Trastuzumabe e pertuzumabe versus acomentimento visceral

Simple item page
dc.TypeRevistas/Boletinspt_BR
dc.contributor.authorINCA
dc.contributor.authorInstituto Nacional de Câncer (Brasil)
dc.contributor.authorInstituto Nacional de Câncer José Alencar Gomes da Silva
dc.contributor.authorSistema Único de Saúde (Brasil)
dc.contributor.authorBrasil. Ministério da Saúde
dc.date.accessioned2022-02-09T17:23:45Z
dc.date.available2022-02-09T17:23:45Z
dc.date.issued2021-12
dc.description2 p.
dc.identifier.urihttp://sr-vmlxaph03:8080/jspui/handle/123456789/5049
dc.language.isoPortpt_BR
dc.publisherINCApt_BR
dc.relation.ispartofseriesAno V, n. 55.
dc.subjectTrastuzumabpt_BR
dc.subjectTrastuzumabpt_BR
dc.subjectNeoplasias de la Mama/tratamiento farmacológicopt_BR
dc.subjectNeoplasias da Mama/tratamento farmacológicopt_BR
dc.subjectBreast Neoplasms/drug therapypt_BR
dc.titleTrastuzumabe e pertuzumabe versus acomentimento visceralpt_BR

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Dezembro_2021 (3).pdf
Size:
482.91 KB
Format:
Adobe Portable Document Format
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.6 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Informe SUS - ONCO 2021